Ray Dalio
BCRX icon

Ray Dalio’s BioCryst Pharmaceuticals BCRX Stock Holding History

Ray Dalio’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.07M Buy
638,054
+402,482
+171% +$3.13M 0.03% 370
2025
Q4 		$1.84M Sell
235,572
-175,931
-43% -$1.27M 0.01% 784
2025
Q3 		$3.12M Buy
+411,503
New +$3.43M 0.01% 608

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Ray Dalio's BCRX Position: Q1 2026 in Review

Ray Dalio increased its BioCryst Pharmaceuticals (BCRX) stake by 171% in Q1 2026, buying an estimated $3.13M and bringing the position to 638,054 shares worth $6.07M. The position accounts for 0.03% of the portfolio, ranked #370.

Ray Dalio first reported a position in BCRX in Q3 2025 and has held it in 3 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Ray Dalio held 638,054 shares of BioCryst Pharmaceuticals worth $6.07M as of Q1 2026.
  • Ray Dalio bought 402,482 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $3.13M.
  • BioCryst Pharmaceuticals made up 0.03% of Ray Dalio's portfolio in Q1 2026, its #370 holding.
  • Ray Dalio first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Bridgewater Associates's 13F filing for Q1 2026, filed 15 May 2026.